Regulatory Reckoning: Navigating the FDA's Laboratory Developed Tests Regulation

February 2024



Maximilian Schmid, M.D.

Stephane Budel, Ph.D.

DeciBio

Table of Contents

Executive Summary

The FDA's impending LDT rule, slated for finalization in April 2024, ushers in a transformative shift in the regulatory landscape for laboratory-developed tests (LDTs), bringing them under the same stringent oversight as in vitro diagnostics (IVDs). This comprehensive rule, aimed at safeguarding patient safety and ensuring diagnostic excellence, presents a critical juncture for laboratories utilizing LDTs and life science tools and diagnostic companies whose products form the backbone of LDT workflows. To effectively navigate this regulatory transition, life science tools and diagnostic companies must embark on a proactive strategy, encompassing reassessing their product portfolios, enhancing regulatory and clinical development capabilities, adhering to stringent quality standards, and maintaining close engagement with regulatory authorities. By embracing this proactive approach, they can effectively adapt to the FDA's LDT rule, positioning themselves for success in the rapidly evolving diagnostic landscape and eventually emerge as industry leaders in the dynamic clinical diagnostics arena.

Background

The FDA's proposed rule for LDTs represents a significant shift in the regulatory landscape, bringing LDTs under the same regulatory oversight as IVDs. The rule is set to transform how LDTs are developed, validated, and utilized in clinical settings.

The key highlights include:

- **Reclassification of LDTs:** LDTs will now be classified as IVDs, making them subject to the regulatory framework of the Federal Food, Drug, and Cosmetic Act (FD&C Act).
- **Comprehensive Oversight:** The rule proposes comprehensive oversight that includes registration, listing, quality system requirements, and adverse event reporting for LDTs.
- **Rigorous Test Validation**: The proposal requires test providers to demonstrate the analytical and clinical validity of their tests. This includes stringent test methodology and validation data to ensure that the tests meet high standards of accuracy and reliability for their intended use.

Table 1: Comparison Table - Changes vs. Status Quo

Aspect	Status Quo	Proposed Change
Classification	LDTs not classified as IVDs	LDTs as IVDs
Oversight	Limited or no FDA oversight	Full FDA oversight
Quality System	Not uniformly required	Mandatory compliance
Adverse Event Reporting	Voluntary or not required	Mandatory

The FDA intends to phase out its enforcement discretion policy for LDTs over a five-year period, beginning in April, 2025. This phased approach will provide limited time for laboratories operating with LDTs to comply with the new regulatory requirements.

The specific timeline for the phaseout of enforcement discretion will be finalized in the final rule. However, the FDA has indicated that low-risk LDTs will be the first to transition to the new regulatory framework, followed by moderate-risk and high-risk LDTs.

Table 2: Phases Implementation Timeline of the FDA LDT Rule

Milestone	Deadline	Requirements
Baseline quality management system	**April 2025** (>1 year after Rule is published)	Customer complaint handling, Adverse Event reporting, Corrections and removals initiation, Correction and removals reporting
Registration & Listing	April 2026 (>2 years after Rule is published)	Laboratory/company registration, Device (LDT) risk classification & listing on FDA website, Compliant labeling, Truthful & not misleading advertising & promotion materials
Device Current Good Manufacturing Practices (CGMP) and Quality Management (QM)	April 2027 (>3 years after Rule is published)	FDA compliant Quality Management System (QMS) with the following key elements: Design controls, Purchasing / supplier controls, Acceptance activities, e.g., receiving, in-process, and finished device acceptance, Corrective and preventative actions, Records requirements
Premarket review for high-risk IVDs	October 2027 (>3.5 years after Rule is published)	Submission of all modules of a Premarket Application (PMA), Mandatory on-site FDA inspection of QMS triggered by submission of the first module, No interruption of access to LDTs that were on the market at the point of submission
Premarket review for moderate and low-risk IVDs	April 2028 (>4 years after Rule is published)	Submission of a 510(k) or a De Novo request, No interruption of access to LDTs that were on the market at the point of submission, Post-clearance inspection of facility/LDT

Implications of the FDA LDT Rule Proposal

The proposed FDA LDT rule significantly impacts both laboratories operating with LDTs and life science tools and diagnostic companies whose products form the backbone of LDT workflows.

For laboratories, this rule necessitates a strategic shift towards meeting stringent regulatory requirements, including validation of test accuracy and reporting standards. The increased regulatory oversight will likely lead to higher operational costs and a need for enhanced technical and compliance expertise.

Table 3: Implications for Laboratories Operating LDTs

Aspect	Implication for Laboratories Operating LDTs
Regulatory Compliance	Increased need for adherence to FDA guidelines, including registration, listing, and adverse event reporting.
Quality Management Systems	Implementation of robust quality systems in compliance with FDA standards, potentially requiring significant process modifications.
Clinical and Analytical Validity	Requirement to demonstrate both clinical and analytical validity of LDTs, leading to additional validation studies and data analysis.
Reporting and Documentation	Enhanced documentation and reporting responsibilities, including medical device reporting and response to adverse events.
Financial Impact	Likely increase in operational costs due to compliance requirements and possible need for additional personnel or expertise.

The proposed FDA LDT rule will significantly impact laboratories using LDTs, particularly those not operating at a profit. The additional complexities and financial strain from compliance requirements may lead to the withdrawal of certain LDTs from the market. Also laboratories might opt for installing IVD workflows produced by life science tools and diagnostic companies instead of validating their own LDTs under the new framework. This shift presents a substantial opportunity for these companies to capture increased market share, provided they are prepared with a range of IVD products ready for implementation in laboratory settings.

As laboratories transition from LDTs to IVD products due to the heightened regulatory environment, we expect an increasing demand for IVD-compliant solutions. This scenario demands that life science tools and diagnostic companies strategically realign their product portfolios, placing a greater emphasis on IVD products versus Research Use Only (RUO) products. While this transition may require significant investments in regulatory approvals and quality systems, it also offers an opportunity to capture a larger share of the evolving diagnostics market, reshaping market dynamics and competitive landscapes.

The FDA LDT rule's impact extends far beyond compliance, ushering in a transformative paradigm shift in the way life science tools and diagnostic companies approach their products. In response to this regulatory overhaul, these companies must embark on a strategic pivot from a technology-centric mindset to one that is profoundly patient-centered. This pivotal transformation demands a heightened focus on investing in clinical studies and developing medical value products, particularly in cutting-edge fields like next-generation sequencing and molecular diagnostics. The rule effectively nudges companies towards prioritizing the clinical relevance and impact of their technologies, realigning product development with patient needs and stringent regulatory mandates. This patient-centric approach holds immense promise for fostering more effective diagnostic solutions, ultimately contributing to a significant uplift in patient care outcomes.

Table 4: Opportunities and Challenges for Life Science Tools and Diagnostic Companies in the Post-LDT Rule Era

Impact	Description
Increased Demand for IVD-Compliant Products	As laboratories shift from LDTs to IVD products, there will be a growing demand for IVD-compliant solutions from life science tools and diagnostic companies.
Strategic Portfolio Realignment	Companies will need to strategically realign their product portfolios, focusing more on IVD products and less on RUO products.
Regulatory Approvals and Quality System Investments	The transition to IVD products may require significant investments in regulatory approvals and quality systems.
Investments in Clinical Development and Medical Affairs Capabilities	Companies will need to invest in strengthening their clinical development and medical affairs capabilities to support the development and marketing of IVD products.
Opportunity for Market Expansion	This shift presents an opportunity for companies to expand their market share in the evolving diagnostics sector.
Reshaping Market Dynamics and Competitive Landscapes	The new regulatory landscape could lead to a reshuffling of market dynamics and competitive positioning among life science tools and diagnostic companies.



Strategies for Life Science Tools and Diagnostic Companies to Thrive in the Post-LDT Rule Era

To effectively navigate the changing regulatory landscape brought about by the FDA's LDT rule, life science tools and diagnostic companies can adopt a comprehensive approach that encompasses four key strategies:

1. Reassessing Product Portfolio and Product Development Roadmap

Life science tools and diagnostic companies must critically evaluate their existing product portfolios and product development roadmaps in light of the new regulatory requirements. This assessment should involve:

- **Identifying products that are impacted by the new rule:** Companies need to determine which of their products are commonly used in LDTs and will be subject to the new regulatory framework.
- **Evaluating which products might benefit from turning into an IVD solution:** For products that are frequently used in LDTs and are subject to the new rule, companies should assess whether it makes strategic and financial sense to transition them to an IVD platform. This evaluation should consider factors such as market demand, regulatory complexity, and the company's capabilities.
- **Redefining product development priorities**: Companies should realign their product development priorities, focusing on high-potential IVD products that can facilitate compliance with the new regulatory requirements for their customers. This may involve prioritizing the development of IVD versions of existing RUO products or pursuing entirely new IVD innovations. Simultaneously, companies should carefully evaluate the continued development and maintenance of RUO products to determine if they remain viable in the post-LDT rule era.



2. Enhancing Regulatory and Clinical Development and Medical Affairs Capabilities

The new regulatory landscape necessitates a strengthening of regulatory and clinical development and medical affairs capabilities. This includes:

- **Building regulatory expertise:** Companies must proactively establish or expand their regulatory teams with in-depth knowledge of FDA regulations, including the premarket approval (PMA) process. This expertise will be crucial for navigating the complexities of the new regulatory framework.
- **Strengthening clinical development capabilities:** Companies need to significantly enhance their clinical development capabilities to conduct rigorous studies that demonstrate the analytical and clinical validity of their IVD products. This entails conducting comprehensive clinical trials to ensure that the products meet the high standards of accuracy and reliability demanded by the new regulatory regime.
- **Developing medical affairs proficiency:** Companies must elevate their medical affairs expertise to effectively communicate the clinical and regulatory aspects of their products to laboratory customers, healthcare professionals, and regulatory bodies. This includes providing clear and concise information about the product's benefits, risks, and applicability, fostering trust and understanding among key stakeholders.

3. Ensuring Adherence to Quality Standards

Life science tools and diagnostic companies must make sure they have implemented and maintain robust quality systems that comply with FDA standards. This includes:

- **Establishing a comprehensive quality management system (QMS):** Companies must establish and maintain a comprehensive QMS that aligns with FDA guidelines and encompasses all aspects of product development, manufacturing, and post-market surveillance. This system should meticulously document processes, procedures, and controls to ensure the consistent production of high-quality products.
- **Implementing quality control and quality assurance (QC/QA) procedures:** Companies must implement rigorous QC/QA procedures to monitor and verify product quality at every stage of the development and manufacturing process. These procedures should include comprehensive testing protocols, calibration checks, and ongoing inspections to ensure products meet the highest standards of accuracy, precision, and reliability.
- **Ensuring effective complaint handling and corrective and preventive action (CAPA) processes:** Companies must establish and maintain efficient complaint handling procedures to promptly investigate and address customer feedback. This includes thoroughly examining complaints, identifying root causes, and implementing corrective actions to prevent recurrence. A robust CAPA system enables companies to continuously improve product

4. Engaging with Regulatory Bodies and Keeping Abreast of FDA Expectations

Active engagement with regulatory bodies and staying abreast of evolving FDA expectations is crucial for success in the post-LDT rule era. This includes:

- **Building relationships with FDA:** Companies should actively cultivate relationships with FDA regulators to gain insights into their expectations, clarify regulatory interpretations, and foster a collaborative approach. This involves establishing open communication channels, attending FDA meetings and workshops, and seeking guidance on specific product development and regulatory matters.
- **Participating in FDA consultations and workshops:** Companies should actively participate in FDA consultations and workshops to stay informed about upcoming regulatory changes, emerging best practices, and the latest interpretation of guidelines. These engagements provide valuable opportunities to clarify regulatory uncertainties, seek practical advice, and adapt strategies accordingly.
- **Monitoring FDA guidance documents and updates:** Companies should establish a robust monitoring system to stay abreast of the latest FDA guidance documents, updates, and regulatory announcements. Regularly reviewing and analyzing these resources ensures that products and processes remain compliant with the evolving regulatory landscape.

Table 5: Essential Strategies for Life Sciences Tools and Diagnostics Companies in the Post-LDT Rule Era

Strategy	Description
Reassessing Product Portfolio and Product Development Roadmap	• Identify products that fall under the scope of the new rule. • Evaluate which products might benefit from turning into an IVD. • Redefine product development priorities. • Prioritize the development of high potential IVD products. • Carefully evaluate the continued development and maintenance of RUO products.
Enhancing Regulatory and Clinical Development and Medical Affairs Capabilities	• Build regulatory expertise. • Strengthen clinical development capabilities. • Develop medical affairs proficiency. • Establish or expand regulatory teams with expertise in FDA regulations. • Be prepared to conduct rigorous studies to demonstrate the analytical and clinical validity of IVD products • Enhance communication with laboratory customers, healthcare professionals, and regulatory bodies.
Ensuring Adherence to Quality Standards	• Establish a comprehensive quality management system (QMS). • Implement quality control and quality assurance (QC/QA) procedures. • Establish effective complaint handling and corrective and preventive action (CAPA) processes. • Develop and implement a comprehensive QMS that addresses all aspects of product development, manufacturing, and post-market surveillance. • Establish and enforce rigorous QC/QA procedures to ensure consistent production of high-quality products. • Implement procedures to effectively handle customer complaints, identify and investigate potential issues, and implement corrective actions to prevent recurrence.
Engaging with Regulatory Bodies and Keeping Abreast of FDA Expectations	• Build relationships with FDA regulators. • Participate in FDA consultations and workshops. • Monitor FDA guidance documents and updates. • Attend regulatory meetings and participate in FDA guidance workshops. • Share experiences and learn from other companies. • Stay informed about upcoming regulatory changes and best practices.

Conclusion

As the FDA's LDT rule approaches finalization, life science tools and diagnostic companies face a pivotal moment. The new regulatory landscape presents both challenges and opportunities, demanding a proactive and strategic approach to ensure compliance and seize new market opportunities. By embracing the strategies outlined in this whitepaper – reassessing product portfolios, enhancing regulatory and clinical development capabilities, ensuring adherence to stringent quality standards, and engaging with regulatory bodies – companies can effectively navigate the regulatory transition and emerge as leaders in the evolving diagnostic landscape.

We invite you to engage with us to explore these critical topics further and gain insights into tailored strategies to address your specific needs. Our team of experts is dedicated to supporting life science tools and diagnostic companies in meeting the challenges and seizing the opportunities presented by the FDA's LDT rule. Together, we can develop tailored strategies and solutions to ensure successful adaptation and continued advancement in the clinical diagnostics arena.



About the Authors

Maximilian Schmid, M.D.
Senior Advisor

Dr. Maximilian Schmid, a distinguished healthcare leader and senior advisor, bridges the gap between clinical practice and commercial leadership. Leveraging his comprehensive background in clinical medicine, academic research, and management consulting, he guides diagnostics companies through the full product lifecycle and international business expansion. Renowned for his strategic acumen and innovation in diagnostics, Dr. Schmid holds board certifications in Obstetrics & Gynecology with sub-specialties in Maternal-Fetal Medicine and Clinical Genetics. His academic achievements include a habilitation in Obstetrics & Gynecology and a prior Associate Professorship at the Medical University of Vienna, Austria. A prolific author, Dr. Schmid's dedication to advancing medical science is evident in his numerous peer-reviewed publications.

Stephane Budel, Ph.D.
Partner, DeciBio

Dr. Stephane Budel, a partner at DeciBio Consulting, brings over 18 years of experience in life science business consulting, entrepreneurship, and academic research. He specializes in commercializing novel technologies in life science research tools and diagnostics, with a particular focus on genomics and next-generation sequencing. Dr. Budel has a track record of addressing diverse business challenges, including product specification strategy and commercial due diligence. He earned his Ph.D. from Yale University, where he researched the molecular mechanisms of schizophrenia.

About DeciBio

DeciBio is a strategy consulting and market research firm with the mission to accelerate innovation in precision medicine. To learn about how DeciBio can support your strategy or market intelligence needs, visit our website: https://www.decibio.com/ or email Steph Budel at budel@decibio.com. DeciBio has multiple reports that provide additional insights into the topics covered in this whitepaper. Relevant products include:

- NGS Manufacturing Market Report Oncology
- Liquid Biopsy Market Report
- Spatial Biology Market Report
- Life Science Research Tools Market Report
- Digital & Computational Pathology Market Report
- Single Cell Analysis Market Report
- Advisory Board Report: Oncology Comprehensive Genomic Profiling - Current Expert Perspectives
- Advisory Board Report: Pharma R&D Investment and ROI
- Advisory Board Report: Digital Pathology Current Pharma User Perspectives
- Advisory Board Report: MRD
- Advisory Board Report: Real-World Data (RWD) Market - Current Expert Perspectives Advisory
- Board Report: NGS Manufacturer Market
- Advisory Board Report: Advanced & Next-Gen Proteomics Ad Board



DeciBio®